Insys Therapeutics, Inc. (NASDAQ:INSY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers Election of
Directors Appointment of Certain Officers Compensatory
Arrangements of Certain Officers
On May 16, 2017, Insys Therapeutics, Inc. (the Company) announced
it is commencing a search for a new Chief Financial Officer
(CFO). Darryl S. Baker, the Companys current CFO, will remain
with the Company in his current capacity until a successor is
hired. Upon his separation from the Company, Mr. Baker will
receive the benefits and severance to which he is entitled to his
employment agreement, which was previously filed as Exhibit 10.8
to the Companys Form S-1 Registration Statement (No. 333-173154)
on April 25, 2013.A copy of the Companys press release announcing
the CFO transition is attached to this Current Report as Exhibit
99.1.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated May 16, 2017 Announcing Chief |
About Insys Therapeutics, Inc. (NASDAQ:INSY)
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies. Insys Therapeutics, Inc. (NASDAQ:INSY) Recent Trading Information
Insys Therapeutics, Inc. (NASDAQ:INSY) closed its last trading session up +0.06 at 12.18 with 614,062 shares trading hands.
